In this context, fatty acid synthase (FASN) is a rate-limiting enzyme in this process, and several FASN inhibitors, including TVB-3166 and TVB-2640, suppressed tumor growth by 15% in 22Rv1 xenografts (142), and notably, induced up to 97% tumor growth inhibition in combination with paclitaxel (142). The gene discussed is FASN; the disease is neoplasm.